Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Share News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Silence Therapeutics Appoints Mark Rothera As CEO; Annual Loss Widens

Mon, 14th Sep 2020 14:07

(Alliance News) - Silence Therapeutics PLC on Monday said it has appointed experienced biotech executive Mark Rothera as chief executive officer with immediate effect, as the drug discovery company reported a widened interim loss on increased research and development costs.

Rothera also will join the company's board.

Iain Ross, who has been executive chair since December, will now revert back to his previous position of non-executive chair, the company said.

Silence Therapeutics said Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of commercial and operational leadership, including driving the successful build up of multiple biotech companies, predominantly in the field of rare diseases.

Prior to joining Silence, Rothera had served as CEO of Orchard Therapeutics, where he oversaw its transformation from a small UK-based, privately held company with two clinical-stage programmes into a leading gene therapy company with seven clinical-stage programmes and fully integrated capabilities, according to Silence Therapeutics.

For the six months to June 30, Silence Therapeutics recorded a pretax loss of GBP13.3 million compared with a pretax loss of GBP9.6 million, driven by doubled research & development spending to GBP10.2 million from GBP5.1 million with the company's SLN360 and SLN124 product candidates both being prepared for clinical testing.

Revenue for the first half totalled GBP1.1 million versus none a year ago.

Silence Therapeutics ended the period with cash and cash equivalents and term deposits of GBP50.3 million versus GBP33.5 million at December 31, 2019. The increase was driven by the upfront cash payment under the company's collaboration with AstraZeneca PLC.

In March, Silence Therapeutics had announced a strategic collaboration with AstraZeneca to discover, develop and commercialise siRNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases. As part of the collaboration agreement, Silence had received an upfront cash payment of USD20.0 million and AstraZeneca made a USD20.0 million equity investment.

Shares in Silence Therapeutics were down 1.1% at 463.00 pence each in London on Monday afternoon.

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Nov 2021 12:59

IN BRIEF: Silence Therapeutics to delist from AIM next week

IN BRIEF: Silence Therapeutics to delist from AIM next week

Read more
26 Nov 2021 09:53

Silence Therapeutics to proceed with AIM delisting next week

(Sharecast News) - Silence Therapeutics updated the market on the planned cancellation of its shares on AIM on Friday, which it originally announced on 15 October.

Read more
16 Nov 2021 12:23

TRADING UPDATES: Focusrite profit jumps; Gear4Music strikes bum note

TRADING UPDATES: Focusrite profit jumps; Gear4Music strikes bum note

Read more
16 Nov 2021 11:39

Revenue, expenses rise in third quarter for Silence Therapeutics

(Sharecast News) - Silence Therapeutics said on Tuesday that its revenue increased by £1.2m year-on-year in its third quarter, as a result of the further advancement of its partner programmes, as well as the introduction of additional programmes with its partners.

Read more
5 Nov 2021 18:40

IN BRIEF: Frazier Life picks up 3% interest in Silence Therapeutics

IN BRIEF: Frazier Life picks up 3% interest in Silence Therapeutics

Read more
5 Nov 2021 11:39

Frazier Life Sciences becomes 'important' new Silence Therapeutics shareholder

(Sharecast News) - Novel short interfering ribonucleic acid (siRNA) therapy developer Silence Therapeutics announced on Friday that healthcare-focussed investor Frazier Life Sciences Public Fund had purchased about $20m of its existing shares.

Read more
25 Oct 2021 16:03

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
22 Oct 2021 20:26

IN BRIEF: Silence Therapeutics reports solid progress across pipelines

IN BRIEF: Silence Therapeutics reports solid progress across pipelines

Read more
15 Oct 2021 15:40

CORRECT: Silence Therapeutics to delist from AIM; teams with Hansoh

CORRECT: Silence Therapeutics to delist from AIM; teams with Hansoh

Read more
15 Oct 2021 14:15

IN BRIEF: Silence Therapeutics to delist from AIM; unites with Hansoh

IN BRIEF: Silence Therapeutics to delist from AIM; unites with Hansoh

Read more
15 Oct 2021 12:23

Silence Therapeutics inks collaboration deal with Hansoh Pharmaceutical

(Sharecast News) - Silence Therapeutics announced a collaboration with Hansoh Pharmaceutical Group on Friday, to develop short interfering ribonucleic acids (siRNAs) for three undisclosed targets, leveraging its proprietary 'mRNAi GOLD' platform.

Read more
1 Sep 2021 09:30

Silence promotes John Strafford to head new product development

(Sharecast News) - Silence Therapeutics announced the appointment of John Strafford to the newly-created role of senior vice-president of business development, alliance management and new product development on Wednesday, effective immediately.

Read more
12 Aug 2021 13:56

IN BRIEF: Silence Therapeutics revenue up, new targets with AstraZeneca

IN BRIEF: Silence Therapeutics revenue up, new targets with AstraZeneca

Read more
12 Aug 2021 09:37

Silence Therapeutics losses widen as it progresses programmes

(Sharecast News) - Silence Therapeutics reported revenues from collaborations of £5.8m in its first half on Thursday, up from £1.1m year-on-year, which it put down to its work with AstraZeneca and Mallinckrodt.

Read more
5 Aug 2021 16:18

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.